Stock Events

Stock Events

Claritas Pharmaceuticals 

C$0.03
2
-C$0-0% Monday 22:00

Statistics

Day High
-
Day Low
-
52W High
0.03
52W Low
0.03
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29NovExpected
Q3 2021
Q1 2024
Q2 2024
Q3 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2015
2016
2017
2018
2019
2020
0Revenue
6.52MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLAS-H.V. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap153.59B
Pfizer is a major player in the pharmaceutical industry, developing drugs that can compete directly with Claritas Pharmaceuticals' offerings.
Merck
MRK
Mkt Cap276.38B
Merck produces a wide range of pharmaceutical products that could compete in the same therapeutic areas as Claritas Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical division, develops medications that may overlap with the treatments offered by Claritas Pharmaceuticals.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline focuses on a broad portfolio of drugs, potentially competing in the same niche as Claritas Pharmaceuticals.
Novartis
NVS
Mkt Cap280.79B
Novartis is known for its innovative medicines and could have competing products in the same categories as Claritas Pharmaceuticals.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie operates in similar therapeutic areas and could have drugs that compete with those of Claritas Pharmaceuticals.
AMGEN
AMGN
Mkt Cap185.74B
Amgen, a biotech firm, develops therapies that might directly compete with Claritas Pharmaceuticals' biopharmaceutical products.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb offers a range of prescription medicines that could directly compete with Claritas Pharmaceuticals.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly and Company develops drugs that could be in direct competition with the treatments developed by Claritas Pharmaceuticals.
Sanofi
SNY
Mkt Cap112.08B
Sanofi produces a variety of pharmaceutical products that could compete across several of the same therapeutic areas as Claritas Pharmaceuticals.

About

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.
Show more...
CEO
ISIN
CA1806342061

Listings

OTC Link
US
CLAZF

0 Comments

Share your thoughts

FAQ

What is Claritas Pharmaceuticals stock price today?▼
The current price of CLAS-H.V is C$0.03 CAD — it has decreased by -0% in the past 24 hours. Watch Claritas Pharmaceuticals stock price performance more closely on the chart.
What is Claritas Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Claritas Pharmaceuticals stocks are traded under the ticker CLAS-H.V.
What is Claritas Pharmaceuticals revenue for the last year?▼
Claritas Pharmaceuticals revenue for the last year amounts to 0 CAD.
What is Claritas Pharmaceuticals net income for the last year?▼
CLAS-H.V net income for the last year is 6.52M CAD.
In which sector is Claritas Pharmaceuticals located?▼
Claritas Pharmaceuticals operates in the Other sector.
When did Claritas Pharmaceuticals complete a stock split?▼
Claritas Pharmaceuticals has not had any recent stock splits.